Aprotinin reduces
bleeding and transfusion rates in patients undergoing coronary surgery while on
clopidogrel. However, safety studies have indicated that
aprotinin may have a possible adverse effect related to an increased incidence of thromboembolic events. We therefore studied the adenosinediphosphate (
ADP) mediated platelet aggregation before and after administration of
aprotinin in patients on
clopidogrel. Fifteen
clopidogrel-treated patients with
acute coronary syndrome undergoing coronary surgery were studied.
ADP-mediated platelet aggregation and platelet count ratio (%) were measured before and after a bolus dose [2 x 10(6)
kallikrein inhibiting units (KIU)] of
aprotinin.
Aprotinin induced an increased aggregation in 11 of 15 patients (73%), and a decrease was registered in two patients (13%). The median (25th/75th percentile)
ADP-mediated platelet aggregation before and after
aprotinin was 84% (76/91) and 94% (86/97, P<0.01).
Clopidogrel non-responders with >90% aggregation (n=4) had a median aggregation of 94.5% (91.5/97.5) vs. 82% (73/87, P<0.01) in the responders (n=11). The median increase in platelet aggregation after
aprotinin was 8% (5/20) in the responders vs. 0% (-5.25/3, P<0.01) in the non-responders.
Aprotinin increased
ADP induced platelet aggregation from 84 to 94% in patients on
clopidogrel, which corresponds to a median decrease in relative platelet inhibition of >50%.